Sue Hall, PhD

Dr. Sue Hall joined the Sebela Board of Directors in May 2022, having previously served as Sebela’s Chief Scientific Officer and Head of R&D since 2017 when she had responsibility for the company’s development programs encompassing clinical and regulatory functions as well as quality assurance and technical operations for the marketed products portfolio. Sue has over 35 years in pharmaceutical research and development and has managed a broad range of R&D functions across diverse therapy areas and regulatory environments, overseeing multiple NDA approvals, product launches, in-licensing opportunities and successful life cycle management strategies.

Prior to Sebela Pharmaceuticals, Sue served as Executive Vice President, Chief Scientific Officer and Global Head of R&D for Endo Pharmaceuticals. There, Sue was responsible for the R&D pipeline and life cycle management for the marketed products portfolio of medicines and for the company’s QA activities. Previously, Sue also served as Senior Vice President and Global Head of R&D for Valeant Pharmaceuticals and prior to that, Sue held numerous R&D leadership positions at GlaxoSmithKline, including clinical pharmacology, project management, medical affairs and regulatory.

Sue holds a PhD in Pharmacokinetics from the University of Manchester, U.K., and a BSc in Pharmacology from the University of Leeds, U.K.